The immunologicals group of the Binding Site, San Diego, has added two Mycoplasma pneumoniae antigens to its offering of products for in vitro diagnostic manufacturing and research applications. Both have been designed for use as components in solid-phase enzyme immunoassays, especially enzyme-linked immunosorbent assays.
M. pneumoniae is a very small bacterium and human pathogen that causes the disease mycoplasma pneumonia, a form of atypical bacterial pneumonia related to cold agglutinin disease. M. pneumoniae is characterized by the absence of a typical cell wall, with resulting resistance to many bactericidals. The persistence of M. pneumoniae infections even after treatment is associated with its ability to mimic host cell surface composition.
Children and the elderly are particularly at risk of M. pneumoniae infection, which may manifest with tracheobronchitis and laryngitis. In addition, disorders of the hematopoietic system, the central nervous system, and the cardiovascular system may also occur due to infection.
Both a native and a recombinant version of the antigen are available, with each exhibiting exceptional purity as a result of chromatographic manufacturing techniques. The antigens also demonstrate lot-to-lot consistency and feature shelf-life stability of 10 years from the date of manufacture. The antigens are offered in standard 1.0 mg vials, with larger, bulk configurations also available.
For additional information, visit the Binding Site.
